


CURRICULUM VITAE

NAME: Ronald G. Washburn, M.D.

SOCIAL SECURITY #: _____

ADDRESS: Medical Service/Infectious Diseases (111-ID)
Overton Brooks VA Medical Center
510 East Stoner Avenue
Shreveport, LA 71101



PERSONAL INFORMATION:

Birthplace: _____

Birth Date: _____

Citizenship: _____

EDUCATION:

1976 A.B., Biochemistry, Brown University, Providence, RI

1979 M.D., Duke University School of Medicine, Durham, NC

HONORS AND AWARDS:

POSTDOCTORAL TRAINING:

- 1979-1980** Research Fellow, Infectious Diseases, Duke Hospital, Durham, NC
Supervisor, David T. Durack, M.B., D.Phil.
- 1980-1981** Medical Intern, Duke University Hospital, Durham, NC
Supervisor, James B. Wyngaarden, M.D.
- 1981-1983** Medical Resident, Duke University Hospital, Durham, NC
Supervisor, James B. Wyngaarden, M.D.
- 1983-1987** Medical Staff Fellow, Clinical Mycology Section, Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD; Supervisor, John E. Bennett, M.D.
- 1994** Advanced Training in Molecular Biology, Recombinant DNA; Catholic University of America, Washington, DC, May 9-13, 1994.
- 1996** Sabbatical, Department of Molecular Biology, Myco Pharmaceuticals, Cambridge, MA, 3/1/96 - 8/31/96. Molecular biology of cell wall biosynthesis in *Aspergillus* species. Supervisor, Yigal Koltin, Ph.D.

PROFESSIONAL LICENSURE:

Louisiana
Nevada
North Carolina

EMPLOYMENT:

- 1987-1991** Assistant Professor of Medicine, Section on Infectious Diseases, Bowman Gray School of Medicine, Wake Forest University, Winston-Salem, NC; supervisor, Charles E. McCall, M.D.
- 1991-1998** Associate Professor of Medicine, Section on Infectious Diseases, Bowman Gray School of Medicine, Wake Forest University, Winston-Salem, NC; supervisor, Charles E. McCall, M.D.
- 1998- 1999** Associate Professor of Medicine, Chief of Infectious Diseases, University of Nevada School of Medicine/ Reno VA Medical Center, Reno, Nevada; supervisor, William F. Graettinger, M.D.
- 1999- 2001** Infectious Diseases Consultant, Piedmont Medical Specialists, Winston-Salem, N.C.; supervisor, Richard S. Marx, M.D.
- 2001- present** Professor of Medicine, Section of Infectious Diseases, Louisiana State University Health Sciences Center, Shreveport, LA; Chief of Infectious Diseases, Overton Brooks VA Medical Center, Shreveport, LA; supervisor Robert L. Penn, M.D.

CERTIFICATION:

American Board of Internal Medicine, September 14, 1983

Subspecialty of Infectious Disease, November 11, 1986

Special Purpose Examination (SPEX), Federation of State Medical Boards; February 19, 1998

MEMBERSHIPS:

American College of Physicians (FACP)

Infectious Disease Society of America (Fellow)

American Federation for Medical Research (Southern Section Councilor, 1991-93; National Councilor, 1993-97; Nominating Committee, 1993-97; Public Policy Committee, 1993-97)

American Association for the Advancement of Science

International Society for Human and Animal Mycology

American Society for Microbiology

GRANTS:

VA Merit Review Grant. Molecular basis of natural killer cell defects in cryptococcosis. 2001-2004 — direct costs.

A randomized trial comparing safety of Amphotec and Abelcet. 2002-present. Intermune, Inc., Brisbane, CA. Funds on per capita basis.

A prospective, randomized, double-blind, multicenter pilot study of the safety and efficacy of interferon gamma-1b plus voriconazole versus placebo plus voriconazole in the treatment of invasive aspergillosis and other filamentous fungal infections. 2002-present. National Institute of Allergy and Infectious Diseases, Division of Microbiology and Infectious Diseases, Bethesda, MD; and Intermune, Inc., Brisbane, CA. Funds on per capita basis.

Efficacy of topical antimicrobial acid and immunostimulatory β -glucan in animal models of cutaneous infection. University of Nevada Applied Research Initiative Matching Grant. Co-investigator, Kenneth W. Hunter, Jr., Sc.D., Professor of Microbiology, University of Nevada School of Medicine. Corporate Partner, Macrophage Technologies, Inc., Carson City, NV. 1998-99. — direct costs.

A multiclinic, double-blind, randomized, comparative dose-response study to evaluate the safety, tolerability, and efficacy of L-743,872 vs. amphotericin B in the treatment of fluconazole unresponsive oropharyngeal and esophageal candidiasis in adults. Merck & Co., 1997-98. — direct costs.

Effect of voriconazole on the interaction between *Aspergillus*, type II pneumocytes, and human phagocytic cells. Pfizer Pharmaceuticals. 1997-1998. — direct costs.

A Random Double Blind Comparative Multicenter Study of Fluconazole plus Amphotericin B versus Fluconazole plus Placebo in the Treatment of Candidemia and its Consequences in Non-Neutropenic Patients. Pfizer/NIH Mycoses Study Group. 1995 - 1998. Funds on per capita basis.

Natural killer cell function in the elderly. Bowman Gray School of Medicine/United Way Venture Grant. 1996-97. — direct costs.

NIH Research Career Development Award. *Aspergillus fumigatus* Complement Inhibitor. K 04 AI-01036. 1991-1996 —

American Foundation for AIDS Research. Pathogenesis and Therapy of Cryptococcosis in AIDS. 1993-94. — direct costs.

GRANTS (Continued)

Phase I Study to Evaluate the Safety and Tolerance of RMP-7 Administered with Amphotericin B to Patients with HIV Infection and Cryptococcal Meningitis. Alkermes. 1993-94. _____ direct costs.

NIH First Independent Research Support and Transition Award. *Aspergillus fumigatus* Complement Inhibitor. R29 AI 25037; 1987-1992: _____

Mallinckrodt Foundation Scholarship. Serotype-specific Differences in Pathogenesis of Cryptococcosis. 1989-92; _____ direct costs.

Open Comparative Multicentered Study of Fluconazole vs. Amphotericin B in the Treatment of Candidemia in Non-Neutropenic Patients; 1991-93; Pfizer Pharmaceuticals, Roerig Division; _____ direct costs.

RJR Nabisco Research Scholars Award. Serotype-specific Differences in Pathogenesis of Cryptococcosis. 1989. _____ direct costs..

Edward Livingston Trudeau Scholarship of the American Lung Association; 1987-1990; _____ direct costs..

American Lung Association of North Carolina Supplies Grant; 1987-90 and 1993-95. : _____

National Foundation for Infectious Diseases Young Investigator Award; 1987-88; _____ Matching Grant.

TRAINEES:

_____. July, 1989-1991.

National Foundation for Infectious Diseases/Janssen Pharmaceutica Postdoctoral Fellowship in Medical Mycology. *Aspergillus fumigatus* Complement Inhibitor. 1989-90, _____

_____. July, 1989-June, 1991.

_____. July, 1992 - September, 1995.

National Foundation for Infectious Diseases/Janssen Pharmaceutica Postdoctoral Fellowship in Medical Mycology; Enhancement of Natural Killer Cell-Mediated Anticryptococcal Activity by Arachidonate Metabolites. 1994-95. : _____

_____. July, 1994 - June, 1996.

_____. July, 1996 - March, 1998.

_____. July, 1998 - June, 1999.

AD HOC REVIEWER:

VA Merit Review Board
NIAID Special Emphasis Panel
Canadian National Health Research and Development Program
British Columbia Health Research Foundation

Infection and Immunity
Journal of Infectious Diseases
Clinical Infectious Diseases
Journal of Medical Mycology

COMMITTEES AND ADMINISTRATION:

1987-1993	Director of Recruitment for Infectious Diseases Fellowship Program, BGSM
1990-1998	Member, Drug Information Center Advisory Committee, BGSM
1991-1994	Member, Intramural Research Support Committee, BGSM
1992-1998	Director, Quality Improvement, Section on Infectious Diseases, BGSM
1993-1994	Member, Department Chairman's Opportunity Commission. Advisory committee to make recommendations concerning departmental issues centering on health care reform, BGSM
1995-96	Member, Transgenic Animal Committee, BGSM
1998-1999	Chairman, Hospital Infection Control Committee, Reno VA Medical Center
1998-1999	Member, Biomedical Human Subjects Committee, University of Nevada School of Medicine
1998-1999	Member, Executive Quality Board, Reno VA Medical Center
1998-1999	Member, Biosafety Committee, University of Nevada School of Medicine
1999	Member, Research and Development Committee, Reno VA Medical Center
1999	Chairman, Safety Subcommittee, Research and Development Committee, Reno VA Medical Center
2001-present	Member, Hospital Infection Control Committee, Shreveport VA Medical Center
2002-present	Member, Institutional Review Board, LSU Health Sciences Center

ATTENDING EXPERIENCE:

1988-1999, and 2001-present	Infectious Diseases Consult Service; BGSM, Reno VA Medical Center, then LSU Health Sciences Center and Shreveport VA Medical Center
1988-1999, and 2001-present	General Internal Medicine Inpatient Service; BGSM, Reno VA Medical Center, then Shreveport VA Medical Center
1995-1998	Outpatient General Internal Medicine Preceptor, BGSM
1997-1999, and 2001-present	Infectious Diseases Clinic Preceptor; BGSM, Reno VA Medical Center, then Shreveport VA Medical Center
1998-99	Primary Care Provider, Reno VAMC
1999-2001	Private Infectious Diseases Consults, General Medicine, Antibiotic Review Committee, and Occupational Health; Piedmont Medical Specialists

TEACHING EXPERIENCE:

1988-98, and 2001-present	Lectures on Fungal Infections; 2 nd year curriculum, BGSM then LSU Health Sciences Center
1988-1994, and 2001-present	Physical Diagnosis, BGSM then LSU Health Sciences Center
1988-1999, and 2001-present	Clinical Infectious Diseases Lectures; BGSM, University of Nevada School of Medicine, then LSU Health Sciences Center

INVITED LECTURES:

Washburn, R.G. Biochemistry of inefficient binding of complement component C3 to *Cryptococcus neoformans* variety *gattii*. International Conference on *Cryptococcus* and Cryptococcosis. Jerusalem, Israel, 1989.

Washburn, R.G. Host defenses against invasive *Aspergillus* infection. XIth Congress of the International Society for Human and Animal Mycology. Montreal, Canada. 1991.

Washburn, R.G. Potential contribution of polar fungal lipids toward pathogenesis of aspergillosis. XIth Congress of the International Society for Human and Animal Mycology. Montreal, Canada, 1991.

Washburn, R.G., and Julian, N.C. *Aspergillus* Complement Inhibitor: potential virulence factor for invasive aspergillosis. (Young Investigator Award, R.G. Washburn). 7th International Symposium on Infections in the Immunocompromised Host. Boulder, Colorado, 1992.

Washburn, R.G. Role of natural killer cells in defense against cryptococcosis. International Conference on *Cryptococcus* and Cryptococcosis. Paris, France. September, 1996.

PUBLICATIONS:

1. **Washburn, R.G., and Durack, D.T.** Efficacy of ampicillin plus a beta-lactamase inhibitor (CP-45,899) in experimental endocarditis due to *Staphylococcus aureus*. J. Infect. Dis. 144:237-43, 1981.
2. **Washburn, R.G., Tuazon, C.U., and Bennett, J.E.** Phagocytic and fungicidal activity of monocytes from patients with acquired immunodeficiency syndrome. J. Infect. Dis. 151:565-6, 1985.
3. **Washburn, R.G., Bryan, C.S., Di Salvo, A.F., Macher, A.M., and Gallin, J.I.** Visceral botryomycosis caused by *Neisseria mucosa* in a patient with chronic granulomatous disease. J. Infect. Dis. 151:563-4, 1985.
4. **Washburn, R.G., and Bennett, J.E.** Paracoccidioidomycosis case report: Cure with amphotericin B and triple sulfa. J. Med. Vet. Mycology 24:235-7, 1986.
5. **Washburn, R.G., Klym, D.M., Kroll, M.H., and Bennett, J.E.** Rapid enzymatic method for measurement of serum flucytosine levels. J. Antimicrob. Chemother. 17:673-7, 1986.
6. **Washburn, R.G., Hammer, C.H., and Bennett, J.E.** Inhibition of complement by culture supernatants of *Aspergillus fumigatus*. J. Infect. Dis. 154:944-51, 1986.
7. **Washburn, R.G., Gallin, J.I., and Bennett, J.E.** Oxidative killing of *Aspergillus* proceeds by parallel myeloperoxidase-dependent and -independent pathways. Infect. Immun. 55:2088-92, 1987.
8. **Huang, C.M., Kroll, M.H., Ruddell, M., Washburn, R.G., and Bennett, J.E.** An enzymatic method for 5-fluorocytosine. Clin. Chem. 34:59-62, 1988.

9. Bobak, D.A., **Washburn, R.G.**, and Frank, M.M. C1q enhances phagocytosis of *Cryptococcus neoformans* blastospores by human monocytes. J. Immunol., 141:592-7, 1988.
10. **Washburn, R.G.**, Kennedy, D.W., Begley, M.G., Henderson, D.K., and Bennett, J.E. Chronic fungal sinusitis in apparently normal hosts. Medicine, 67:231-47, 1988.
11. **Washburn, R.G.** Bronchopulmonary aspergillosis. In: Kelley, W.N., ed. Textbook of Internal Medicine. Philadelphia: J.B. Lippincott, p. 1897-9, 1989.
12. **Washburn, R.G.** *Streptobacillus moniliformis* (rat-bite fever). In: Mandell, G.L., Douglas, R.G., and Bennett, J.E., eds., Principles and Practice of Infectious Diseases. 3rd ed., New York: J. Wiley and Sons, p. 1762-4, 1989.
13. **Washburn, R.G.** *Spirillum minor* (rat-bite fever). In: Mandell, G.L., Douglas, R.G., and Bennett, J.E., eds., Principles and Practice of Infectious Diseases. 3rd ed., New York: J. Wiley and Sons, p. 1827-8, 1989.
14. **Washburn, R.G.** and Bennett, J.E. Reversal of adrenal glucocorticoid dysfunction in a patient with disseminated histoplasmosis. Ann. Intern. Med., 110:86-7, 1989.
15. Alter, C.L., Levine, P.H., Bennett, J.E., Kessler, C., Rick, M., **Washburn, R.G.**, Gallin, J.I., Miller, R.W., and Auerbach, A.D. Dominantly transmitted hematologic dysfunction clinically similar to Fanconi's anemia. American Journal of Hematology, 32:241-7, 1989.
16. Weber, S.F. and **Washburn, R.G.** Invasive *Aspergillus* infections complicating coronary artery bypass grafting. South. Med. J., 83:584-8, 1990.
17. **Washburn, R.G.**, DeHart, D.J., Agwu, D.E., Bryant-Varela, B.J., Julian, N.C. *Aspergillus fumigatus* complement inhibitor: production, characterization, and purification using hydrophobic interaction-and thin layer-chromatography. Infect. Immun., 58:3508-15, 1990.
18. **Washburn, R.G.**, Bryant-Varela, B.J., Julian, N.C., and Bennett, J.E. Differences in *Cryptococcus neoformans* capsular polysaccharide structure influence assembly of alternative complement pathway C3 convertase on fungal surfaces. Mol. Immunol., 28:465-70, 1991.
19. Jacobson, K.C., **Washburn, R.G.**, and Kuhn, R.E. Binding of C3 to complement resistant trypomastigotes of the Brazil strain of *Trypanosoma cruzi*: evidence for heterogeneity within the strain. J. Parasitol., 78:697-704, 1992.
20. Kappe, R., Levitz, S.M., Cassone, A., and **Washburn, R.G.** Mechanisms of host defense against fungal infection. J. Med. Vet. Mycology, 30 (Suppl 1):167-77, 1992.
21. Rhodes, J.C., Jensen, H.E., Nilius, A.M., Chitambar, C.R., Farmer, S.G., **Washburn, R.G.**, Steele, P.E., and Amlung, T.W. *Aspergillus* and aspergillosis. J. Med. Vet. Mycology, 30 (Suppl 1):51-7, 1992.
22. **Washburn, R.G.** Bronchopulmonary aspergillosis. In: Kelley, W.N., ed. Textbook of Internal Medicine. Philadelphia: J.B. Lippincott, 1730-1, 1992.
23. **Washburn, R.G.** Chronic fungal sinusitis in the nonimmunocompromised host. In: Kaliner, M.A., and Druce, H.M. Sinusitis-Pathophysiology and Treatment. New York: Marcel Dekker, Inc., 205-26, 1993.
24. Rex, J.H., Bennett, J.E., Sugar, A.M., Pappas, P.G., van der Horst, C.M., Edwards, J.E. Jr., **Washburn, R.G.**, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. New England Journal of Medicine, 331:1325-31, 1994.

25. Blaser, M.J., Wang, E., Tummuru, M.K.R., **Washburn, R.G.**, Fujimoto, S., and Labigne, A. High frequency S-layer protein variation in *Campylobacter fetus* revealed by *sap A* mutagenesis. Molecular Microbiology, 14:453-62, 1994.
26. **Washburn, R.G.** *Streptobacillus moniliformis* (rat-bite fever). In: Mandell, G.L., Bennett, J.E., and Dolin, R., eds. Principles and Practice of Infectious Diseases. 4th ed., New York: Churchill Livingstone, 2084-6, 1994.
27. **Washburn, R.G.** *Spirillum minor* (rat-bite fever). In: Mandell, G.L., Bennett, J.E., and Dolin, R., eds. Principles and Practice of Infectious Diseases. 4th ed., New York: Churchill Livingstone, 2155-6, 1994.
28. **Washburn, R.G.**, and Bennett, J.E. Deep mycoses. In: Blaser, M.J., Smith, P.D., Ravdin, J.I., Greenberg, H.B., and Guerrant, R.L. Infections of the Gastrointestinal Tract. New York, New York. Raven Press; 957-66, 1995.
29. Horn, C.A., **Washburn, R.G.**, Givner, L., Peacock J.E., and Pegram, P.S. Azole resistant esophageal candidiasis in patients with AIDS. AIDS, 9:533-5, 1995.
30. Horn, C.A., and **Washburn, R.G.** Anticryptococcal activity of NK cell-enriched peripheral blood lymphocytes from HIV-infected subjects: responses to interleukin-2, interferon-gamma, and interleukin-12. J Infect Dis, 172:1023-7, 1995.
31. Rex, J.H., Bennett, J.E., Sugar, A.M., Pappas, P.G., van der Horst, C.M., Edwards, J.E. Jr., **Washburn, R.G.**, et al. Intravascular catheter exchanges and the duration of candidemia. Clin Infect Dis, 21:994-6, 1995.
32. Barber, B.A., Crotty, J.M., **Washburn, R.G.**, and Pegram, P.S. *Cryptococcus neoformans* myositis in a patient with AIDS. Clin Infect Dis, 21:1510-11, 1995.
33. **Washburn, R.G.** Opportunistic mold infections. In: Esser, L., and Lemke, P.A. The Mycota VI. Heidelberg, Germany. Springer-Verlag; 147-58, 1996.
34. Gonzalez-Valencia, G., Perez-Perez, G.I., **Washburn, R.G.**, and Blaser, M.J. Susceptibility of *Helicobacter pylori* to the bactericidal activity of human serum. Helicobacter, 1:28-33, 1996.
35. Dale, J.B., **Washburn, R.G.**, Marques, M.B., and Wessels, M.R. Hyaluronate capsule and surface M protein in resistance to opsonization of group A streptococci. Infect Immun, 64:1495-1501, 1996.
36. Marosok, R.D., **Washburn, R.G.**, Indorf, A., Solomon, D., and Sherertz, R.J. Contribution of vascular catheter material to the pathogenesis of infection: depletion of complement by silicone elastomer in vitro. J Biomed Materials Research, 245-50, 1996.
37. **Washburn, R.G.** Bronchopulmonary aspergillosis. In: Kelley, W.N., ed. Textbook of Internal Medicine. Philadelphia: J.B. Lippincott, 2000-1, 1996.
38. Parta, M., **Washburn, R.G.**, and Kwon-Chung, K.J. The role of hydrophobic surface protein layers of filamentous fungi in host-pathogen interactions. In: Bossche, V.H., Stevens, D.A., and Odds, F.C. Host-Fungus Interplay. Bethesda, MD. National Foundation for Infectious Diseases; 237-45; 1997
39. DeHart, D.J., Agwu, D.E., Julian, N.C., and **Washburn, R.G.** Binding and germination of *Aspergillus fumigatus* conidia on cultured A549 pneumocytes. J Infect Dis, 175:146-50, 1997.

40. High, K.P., and **Washburn, R.G.** Invasive aspergillosis in mice immunosuppressed with cyclosporin A, tacrolimus (FK506) or sirolimus (rapamycin). J Infect Dis, 175:222-5, 1997.
41. Tsai, H.F., **Washburn, R.G.**, Chang, Y.C., and Kwon-Chung, K.J. *Aspergillus fumigatus arp1* modulates conidial pigmentation and complement deposition. Mol. Microbiol., 26: 175-83, 1997.
42. Ely, E.W., Peacock, J.E., Haponik, E.F., and **Washburn, R.G.** Cryptococcal pneumonia complicating pregnancy. Medicine, 77: 153-67, 1998.
43. **Washburn, R.G.** Fungal sinusitis. In: Remington, J.S. and Swartz, M.N. Current Clinical Topics in Infectious Diseases. 18: 60-74, 1998.
44. Tsai, H.F., Chang, Y.C., **Washburn, R.G.**, Wheeler, M.H., and Kwon-Chung, K.J. The developmentally regulated *alb1* gene of *Aspergillus fumigatus*: its role in modulation of conidial morphology and virulence. J. Bacteriol., 180: 3031-8, 1998.
45. Allos, B.M., Lippy, F.T., Carlsen, A., **Washburn, R.G.**, and Blaser, M.J. Serotype, serum resistance, and ¹²⁵I-C3 binding among *Campylobacter jejuni* strains from patients with Guillain-Barré syndrome or uncomplicated enteritis. Emerging Inf. Dis., 4:263-8, 1998.
46. **Washburn, R.G.** *Streptobacillus moniliformis* (rat-bite fever). In: Mandell, G.L., Bennett, J.E., and Dolin, R., eds. Principles and Practice of Infectious Diseases. 5th ed., Philadelphia: Churchill Livingstone, p. 2422-4, 2000.
47. **Washburn, R.G.** *Spirillum minor* (rat-bite fever). In: Mandell, G.L., Bennett, J.E., and Dolin, R., eds. Principles and Practice of Infectious Diseases. 5th ed., Philadelphia: Churchill Livingstone, p.2518, 2000.
48. **Washburn, R.G.** Rat bite fever. In: Kelley, W.N., ed. Textbook of Internal Medicine. 4th ed., New York: Lippincott Williams and Wilkins, Chapter 293; 2000.
49. Netski, D.M., Tsai, H.-F., Chang, Y.C., DeJong, B.C.H., Kwon-Chung, K.J., and **Washburn, R.G.** Polyketide synthase gene of *Aspergillus fumigatus* is associated with decreases in T_H1 responses. Submitted. 2002.
50. Rex, J.H., Pappas, P.G., Karchmer, A.W., Sobel, J., Edwards, J.E., Hadley, S., Brass, C., Vazquez, J.A., Chapman S.W., Horowitz, H.H., Zervos, M., Lee, J., Babinchak, T., Bradsher, R.W., Cleary, J.D., Cohen, D.M., Danziger, L., Goldman, M., Goodman, J., Hilton, E., Hyslop, N.E., Kett, D.H., Lutz, J., Rubin, R.H., Scheld, W.M., Schuster, M., Simmons, B., Stein, D.K., **Washburn, R.G.**, Mautner, L., Chu, T.C., Panzer, H., Rosenstein, R.B., and Booth, J. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo vs. fluconazole plus amphotericin B as therapy of candidemia and its consequences in non-neutropenic hosts. Submitted. 2002.

APPEARS THIS WAY
ON ORIGINAL

PRESENTATIONS:

1. **Washburn, R.G.**, Edwards, D.J., Perfect, J.R., and Durack, D.T. Ampicillin plus a beta-lactamase inhibitor is effective in experimental nafcillin-sensitive and -resistant *Staphylococcus aureus* endocarditis. 20th Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, LA, # 278, 1980.
2. **Washburn, R.G.**, Tuazon, C.U., and Bennett, J.E. Fungicidal activity of peripheral blood monocytes in acquired immune deficiency syndrome. 24th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, # 876, 1984.
3. **Washburn, R.G.**, Klym, D.M., Kroll, M.H., and Bennett, J.E. Rapid enzymatic method for measurement of flucytosine levels. IXth Meeting International Society for Human and Animal Mycology. Atlanta, GA, # R8-1, 1985.
4. **Washburn, R.G.**, Hammer, C.H., and Bennett, J.E. Inhibition of opsonization by culture supernatants of *Aspergillus fumigatus*. 25th Interscience Conference on Antimicrobial Agents and Chemotherapy. Minneapolis, MN, # 313, 1985.
5. **Washburn, R.G.**, Gallin, J.I., and Bennett, J.E. Hydrogen peroxide is the chief oxygen metabolite by which human mononuclear cells kill *Aspergillus* conidia. American Federation for Clinical Research. Washington, DC, # 536A, 1986.
6. Huang, C.M., Kroll, M.H., Ruddel, M., **Washburn, R.G.**, and Bennett, J.E. A rapid enzymatic assay of flucytosine in serum with a centrifugal analyzer. 39th National Meeting of the American Association of Clinical Chemistry. San Francisco, CA, # 691, 1987.
7. **Washburn, R.G.**, Delga, J.M., Hammer, C.H., and Bennett, J.E. Complement inhibitor from *Aspergillus fumigatus* production, characterization, and partial purification. 27th Interscience Conference on Antimicrobial Agents and Chemotherapy. New York, NY, # 583, 1987.
8. Bobak, D.A., **Washburn, R.G.**, and Frank, M.M. C1q enhances the phagocytosis and killing of *Cryptococcus neoformans* blastospores by human monocytes. 27th Interscience Conference on Antimicrobial Agents and Chemotherapy. New York, NY, # 586, 1987.
9. **Washburn, R.G.**, and Bennett, J.E. *Cryptococcus neoformans* serotypes B and C bind less complement component C3 than serotypes A and D. Xth Congress of the International Society for Human and Animal Mycology. Barcelona, Spain, # O-146, 1988.
10. **Washburn, R.G.**, Kennedy, D.W., Henderson, D.K., and Bennett, J.E. Chronic fungal sinusitis in immunologically normal hosts. Xth Congress of the International Society for Human and Animal Mycology. Barcelona, Spain, # P-175, 1988.
11. **Washburn, R.G.**, and Bryant-Varela, B.J. Inefficient binding of complement component C3 to *Cryptococcus neoformans* serotypes B and C versus A and D: evidence for the importance of side chain substitution of capsular polysaccharide. 89th Annual Meeting of the American Society for Microbiology. New Orleans, LA, # F128, 1989.
12. **Washburn, R.G.**, and Bryant-Varela, B.J. *Aspergillus* complement inhibitor delays clot lysis. 29th Interscience Conference on Antimicrobial Agents and Chemotherapy. Houston, TX, # 1088, 1989.
13. **Washburn, R.G.**, and Bryant-Varela, B.J. Purification of *Aspergillus* complement inhibitor using Phenylsuperose hydrophobic interaction chromatography. American Federation for Clinical Research, Southern Section. New Orleans, LA, # 15 A, 1990.
14. DeHart, D.J., Agwu, D.E., Julian, N.C., and **Washburn, R.G.** *Aspergillus* complement inhibitor: contribution of phospholipids towards inhibitory activity. American Federation for Clinical Research, Washington, DC, # 353 A, 1990.

15. Marosok, R., Carruth, W., **Washburn, R.**, Solomon, D., and Sherertz, R. Opsonic requirements for the killing of *S. aureus* on vascular catheter surfaces made of different materials. American Federation for Clinical Research, Washington, DC, # 391 A, 1990.
16. **Washburn, R.G.**, and Julian, N.C. *Aspergillus fumigatus* complement inhibitor: ablation of activity by properdin. American Federation for Clinical Research, Southern Section. New Orleans, # 951 A, 1991.
17. DeHart, D., Agwu, D., and **Washburn, R.** Binding and germination of *Aspergillus fumigatus* conidia on cultured type II pneumocytes. XIth Congress of the International Society for Human and Animal Mycology. Montreal, Canada, # PS 4.57, 1991.
18. **Washburn, R.**, Church, D., Seeds, M., Bass, D., and Julian, N. Phagocytosis and fungicidal activity of polymorphonuclear neutrophils against the four serotypes of *Cryptococcus neoformans*. XIth Congress of the International Society for Human and Animal Mycology. Montreal, Canada, # PS 4.39, 1991.
19. **Washburn, R.G.**, Julian, N.C., Wang, E., and Blaser, M.J. Inhibition of complement by surface array protein from *Campylobacter fetus* ssp. *fetus*. 31st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, # 1328, 1991.
20. **Washburn, R.G.**, and Julian, N.C. Quantitative binding of complement component C3 to *Aspergillus* conidia. American Federation for Clinical Research, Southern Section. New Orleans, LA, # 863 A, 1992.
21. **Washburn, R.G.**, and Julian, N.C. Evidence for surface expression of a complement inhibitor on *Aspergillus* conidia. American Federation for Clinical Research. Baltimore, MD, # 289A, 1992.
22. Church, D., and **Washburn, R.** Comparison of virulence among serotypes of *Cryptococcus neoformans* in a murine inhalation model. American Society for Microbiology. New Orleans, LA, 1992.
23. **Washburn, R.G.**, and Julian, N.C. Purification of *Aspergillus* complement inhibitor with reverse phase high pressure liquid chromatography. Infectious Diseases Society of America. New Orleans, LA, # 66, 1993.
24. **Washburn, R.G.**, and Julian, N.C. Congenitally C5-deficient mice have increased susceptibility to invasive aspergillosis. Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, LA, # 54, 1993.
25. Rex, J.H., Bennett, J.E., Sugar, A.M., Edwards, J.E. Jr., van der Horst, C.M., **Washburn, R.G.**, Dine, A.P., Webb, C.D., and the Candidemia Study Group. Fluconazole vs amphotericin B for treatment of candidemia: results of a randomized, multicenter trial. Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, LA, # 805, 1993.
26. Horn, C.A., and **Washburn, R.G.** Human natural killer cells inhibit growth of *Cryptococcus neoformans*. American Federation for Clinical Research, Southern Section. New Orleans, LA, # 765A, 1994.
27. **Washburn, R.G.**, Julian, N.C., Chang, Y.C., and Kwon-Chung, K.J. Pigment production by *Aspergillus fumigatus* conidia influences alternative complement pathway-mediated opsonization. American Federation for Clinical Research, Baltimore, MD, # 153A, 1994.

28. Horn, C.A., and **Washburn, R.G.** Impaired natural killer cell activity against *Cryptococcus neoformans* in HIV-infected subjects. Interscience Conference on Antimicrobial Agents and Chemotherapy. Orlando, Fla, # G16, 1994.
29. Horn, C.A., **Washburn, R.G.**, Peacock, J.E., Jr., and Pegram, P.S. Azole-resistant, progressive oropharyngeal and esophageal candidiasis in patients with AIDS: a re-emerging indication for amphotericin B. Interscience Conference on Antimicrobial Agents and Chemotherapy. Orlando, Fla, # I 221, 1994.
30. **Washburn, R.G.**, Parta, M., Chang, Y.C., Julian, N.C., and Kwon-Chung, K.J. Binding of fibrinogen to rodletless *Aspergillus nidulans* is impaired. Eighteenth Fungal Genetics Conference, Asilomar, CA, Abstract # 60, p. 100, 1995.
31. Horn, C.A., and **Washburn, R.G.** Effect of IL-12 on anticytotoxic activity of natural killer cells from HIV-infected patients. American Federation for Clinical Research, San Diego, CA, # 217A, 1995.
32. Parta, M., **Washburn, R.G.**, Chang, Y.C., and Kwon-Chung, K.J. The role of hydrophobic surface protein layers of filamentous fungi in host-pathogen interactions. 5th Symposium on Topics in Mycology, Host-Fungus Interplay, Stanford, CA, 1995.
33. High, K.P., and **Washburn, R.G.** Disseminated aspergillosis in mice immunosuppressed with cyclosporin, tacrolimus (FK506), or sirolimus (rapamycin). Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1995.
34. **Washburn, R.G.**, Bartlett, J.A., Forthal, D.N., Graney, W.F., et al. Phase I/II study of RMP-7 and amphotericin B for cryptococcal meningitis in AIDS. Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1995.
35. Horn, C.A., and **Washburn, R.G.** IL-12-stimulated anticytotoxic activity in natural killer cells from HIV patients: inhibition by antiperforin antibody. Infectious Diseases Society of America, San Francisco, CA, # 32, 1995.
36. **Washburn, R.G.**, Nana-Sinkam, P., Bruggeman, L.A., and Klotman, P.E. HIV transgenic mouse model for disseminated cryptococcosis. American Federation for Clinical Research, Washington, DC, # 321A, 1996.
37. **Washburn, R.G.**, Chang, Y.C., and Parta, M. *Aspergillus* hydrophobic surface protein layers influence virulence, fibrinogen, and complement deposition. American Society for Microbiology, New Orleans, LA, # F42, 1996.
38. Tsai, H.F., **Washburn, R.G.**, Chang, Y.C., and Kwon-Chung, K.J. Isolation of ARP1 gene that modulates complement activation by *Aspergillus fumigatus* conidia. American Society for Microbiology, New Orleans, LA, # F111, 1996.
39. **Washburn, R.G.**, Horn, C.A., Horton, J.M., Falloon, J., and Bennett, J.E. Defective anticytotoxic activity of natural killer cells from non-HIV-infected individuals with cured or suppressed cryptococcosis. American Federation for Medical Research, Washington, DC, 1997.
40. Tsai, H.F., **Washburn, R.G.**, Chang, Y.C., and Kwon-Chung, K.J. Molecular dissection of pigment synthesis in *Aspergillus fumigatus*: the genes and their effects on C3 binding. American Society for Microbiology, Miami Beach, Fla, 1997.

41. **Washburn, R.G.**, Charles, C., Johnson, J., and Morris, J.G. Binding of complement component C3 to serum-resistant *Vibrio vulnificus* and *V. cholerae* is impaired. Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada, 1997.
42. Ely, W., Peacock, J., Haponik, E., and **Washburn, R.** Cryptococcal pneumonia complicating pregnancy: report of 4 cases. Infectious Diseases Society of America, San Francisco, CA, # 401, 1997.
43. **Washburn, R.G.**, Tsai, H.F., Chang, Y.C., Wheeler, M.H., and Kwon-Chung, K.J. Effect of *alb1* gene of *Aspergillus fumigatus* on opsonophagocytosis. American Society for Microbiology, F-10, Atlanta, GA, 1998.
44. Koul, A., Jessup, C.J., Deluca, D.J., Elnicky, C.J., Nuñez, M., **Washburn, R.G.**, and Ghannoum, M.A. Phospholipase B is the predominant phospholipase secreted by *Aspergillus fumigatus* and *A. flavus*. American Society for Microbiology, F-78, Atlanta, GA, 1998.
45. Tsai, H.F., Chang, Y.C., **Washburn, R.G.**, Wheeler, M.H., and Kwon-Chung, K.J. A developmentally-regulated *alb1* gene of *Aspergillus fumigatus* influences conidial morphology and virulence. American Society for Microbiology, F-60, Atlanta, GA, 1998.
46. Ray, K.C., Mesnage, S., **Washburn, R.**, Mock, M., Fouet, A., and Blaser, M. Complement binding to *Bacillus anthracis* mutants lacking surface structures. American Society for Microbiology, B-418, Atlanta, GA, 1998.
47. Nuñez, M., Halsey, T., Rye, A., and **Washburn, R.** Voriconazole protects A549 pneumocytes from invasion by *Aspergillus fumigatus*. Infectious Diseases Society of America, # 206, Denver, Colorado, 1998.
48. Netski, D.M., Tsai, H.-F., Chang, Y.C., Kwon-Chung, K.J., and **Washburn, R.G.** *Alb1* gene of *Aspergillus fumigatus* decreases interferon- γ secretion by human mononuclear cells. American Society for Microbiology, F-86, Chicago, IL, 1999.
49. Netski, D., Hudig, D., Buxton, I., Zhong, Q., Grinsell, M., Kozel, T., and **Washburn, R.G.** *Cryptococcus neoformans* glucuronoxylomannan (GXM) binds to human mononuclear cells. International Conference on *Cryptococcus* and Cryptococcosis, London, UK, 1999.
50. Rex, J.H., Pappas, P.G., Karchmer, A.W., Sobel, J., Edwards, J.E., Hadley, S., Brass, C., Vazquez, J.A., Chapman, S.W., Horowitz, H., Zervos, M., Lee, J., Babinchak, T., Bradsher, R.W., Cohen, D.M., Danziger, L., Goldman, M., Goodman, J., Hilton, E., Horton, J., Hyslop, N.E., Kett, D.H., Lutz, J., Rubin, R.H., Scheld, W.M., Schuster, M., Simmons, B., Stein, D.K., **Washburn, R.G.**, Mautner, L., Chu, T.C., Panzer, H., Rosenstein, R., and Booth, J. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo vs. fluconazole + amphotericin B as treatment of candidemia in non-neutropenic patients. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, 681a, Chicago, IL, 2001.
51. **Washburn, R.G.**, Brooks, K.L., and Dauenhauer, S.A. Invasive *Bacillus* spp. infections during a window replacement project at a teaching hospital. Submitted. 103rd General Meeting of the American Society for Microbiology, Washington, D.C., 2003.